Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Healthy return on equity of 20.0%
Concerns1
- Negative free cash flow (βΉ14 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 8 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.20 K Cr | β | βΉ373.00 Cr | β | β | 20.6% | 18.0% | 22.3% |
| Mar 2024 | βΉ1.02 K Cr | β | βΉ305.00 Cr | β | β | 20.0% | 19.2% | 28.2% |
| Mar 2023 | βΉ853.00 Cr | β | βΉ238.00 Cr | β | β | 18.4% | 19.6% | 33.0% |
| Mar 2022 | βΉ713.00 Cr | β | βΉ179.00 Cr | β | β | 16.2% | 15.6% | -23.8% |
| Mar 2021 | βΉ617.00 Cr | β | βΉ235.00 Cr | β | β | 23.5% | 20.5% | 39.1% |
| Mar 2020 | βΉ512.00 Cr | β | βΉ169.00 Cr | β | β | 21.9% | 17.4% | 43.2% |
| Mar 2019 | βΉ436.00 Cr | β | βΉ118.00 Cr | β | β | 17.3% | 28.2% | 18.0% |
| Mar 2018 | βΉ340.00 Cr | β | βΉ100.00 Cr | β | β | 16.8% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,125 |
| Total Expenses | 685 |
| EBIT / Operating Profit | 440 |
| OPM % | 39% |
| Other Income | 51 |
| Finance Costs | 0 |
| Depreciation & Amortisation | 64 |
| Profit Before Tax | 427 |
| Tax % | - |
| Net Profit / PAT | 322 |
| EPS (βΉ) | 30.73 |
| Dividend Payout % | - |
Peer Comparison
Technology sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Concord Biotech Limitedthis co. | βΉ14.12 K Cr | βΉ1.20 K Cr | 43.90 | 7.77 | 30.04 | 18.0% |
| Bharti Airtel Ltd. | βΉ12.19 L Cr | βΉ1.09 L Cr | 50.40 | 8.31 | 27.19 | 15.8% |
| Tata Consultancy Services Ltd. | βΉ11.84 L Cr | βΉ2.15 L Cr | 24.20 | 13.91 | 18.91 | 6.2% |
| Infosys Ltd | βΉ6.48 L Cr | βΉ1.37 L Cr | 24.20 | 7.17 | 16.31 | 5.9% |
| HCL Technologies Ltd | βΉ4.52 L Cr | βΉ51.10 K Cr | 36.80 | 14.48 | β | 6.2% |
| Bharat Electronics Ltd. | βΉ3.02 L Cr | βΉ23.66 K Cr | 53.30 | 14.23 | 51.32 | 17.3% |
| Wipro Ltd. | βΉ2.77 L Cr | βΉ67.29 K Cr | 23.00 | 4.29 | 18.85 | 0.8% |
| Industry Average | β | βΉ10.05 K Cr | 69.99 | 8.58 | 66.75 | 22.0% |